Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis

Biomarkers for stratifying patients that could benefit from immune checkpoint inhibitors are necessary. Tumour mutation burden has recently become a promising biomarker in cancer, but the associations between tumour mutation burden and outcomes of immune checkpoint inhibitors treatment were not well-documented in present studies.We searched PubMed, Web of Science and EMBASE databases up to 1 October 2019. Studies evaluated the association...